HK1058003A1 - Sustained release ranolazine formulations - Google Patents
Sustained release ranolazine formulationsInfo
- Publication number
- HK1058003A1 HK1058003A1 HK04100863A HK04100863A HK1058003A1 HK 1058003 A1 HK1058003 A1 HK 1058003A1 HK 04100863 A HK04100863 A HK 04100863A HK 04100863 A HK04100863 A HK 04100863A HK 1058003 A1 HK1058003 A1 HK 1058003A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sustained release
- release ranolazine
- ranolazine formulations
- formulations
- sustained
- Prior art date
Links
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960000213 ranolazine Drugs 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/520,932 US6479496B1 (en) | 1998-09-10 | 2000-03-08 | Methods for treating angina with ranolazine |
PCT/US2001/007287 WO2001066093A2 (en) | 2000-03-08 | 2001-03-07 | Sustained release ranolazine formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1058003A1 true HK1058003A1 (en) | 2004-04-30 |
Family
ID=24074628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04100863A HK1058003A1 (en) | 2000-03-08 | 2004-02-10 | Sustained release ranolazine formulations |
Country Status (17)
Country | Link |
---|---|
US (1) | US6479496B1 (xx) |
EP (1) | EP1263439A2 (xx) |
JP (2) | JP4108980B2 (xx) |
CN (1) | CN1323664C (xx) |
AU (3) | AU4009201A (xx) |
BR (1) | BR0109091A (xx) |
CA (1) | CA2402222C (xx) |
CZ (1) | CZ20022996A3 (xx) |
HK (1) | HK1058003A1 (xx) |
HU (1) | HUP0204409A3 (xx) |
IL (1) | IL151575A0 (xx) |
MX (1) | MXPA02008654A (xx) |
NO (1) | NO20024270L (xx) |
NZ (1) | NZ521292A (xx) |
PL (1) | PL357273A1 (xx) |
RU (1) | RU2002126615A (xx) |
WO (1) | WO2001066093A2 (xx) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
IL165304A0 (en) * | 2002-05-21 | 2006-01-15 | Cv Therapeutics Inc | Method of treating diabetes |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
EP1648407A4 (en) | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION |
JP2006528189A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質産物、その使用法および製剤 |
US8425936B2 (en) | 2003-07-21 | 2013-04-23 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
AU2004264939A1 (en) | 2003-08-11 | 2005-02-24 | Middlebrook Pharmaceuticals, Inc. | Robust pellet |
US8062672B2 (en) | 2003-08-12 | 2011-11-22 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
WO2005023184A2 (en) | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
US8460710B2 (en) | 2003-09-15 | 2013-06-11 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
WO2006014427A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
US20060177502A1 (en) * | 2005-01-06 | 2006-08-10 | Srikonda Sastry | Sustained release pharmaceutical formulations |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
CN100455288C (zh) * | 2006-06-26 | 2009-01-28 | 哈药集团制药总厂 | 一种盐酸雷诺嗪制剂配方 |
US20080031947A1 (en) * | 2006-07-24 | 2008-02-07 | Cima Labs Inc. | Orally dissolvable/disintegrable lyophilized dosage forms containing protected |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
JP2010518181A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
US20080193530A1 (en) * | 2007-02-13 | 2008-08-14 | Brent Blackburn | Use of ranolazine for the treatment of non-coronary microvascular diseases |
CA2678319A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
ATE509015T1 (de) * | 2007-03-07 | 2011-05-15 | Concert Pharmaceuticals Inc | Deuterierte piperazinderivate als verbindungen gegen angina |
WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
MX2009012957A (es) * | 2007-05-31 | 2010-03-03 | Cv Therapeutics Inc | Metodo para tratar diabetes. |
EP2170333B1 (en) * | 2007-05-31 | 2013-02-20 | Gilead Sciences, Inc. | Ranolazine for elevated brain-type natriuretic peptide |
AU2008266124A1 (en) * | 2007-06-13 | 2008-12-24 | Auspex Pharmaceuticals, Inc. | Substituted piperazines |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
WO2009100380A1 (en) * | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of ranolazine for treating pain |
JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ, インコーポレイテッド | Cns障害の治療のためのラノラジン |
NO3175985T3 (xx) | 2011-07-01 | 2018-04-28 | ||
AU2012312266A1 (en) | 2011-09-21 | 2013-05-02 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス,インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症(PH-HF-pEF)を治療するためのレボシメンダン |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
NZ234184A (en) * | 1989-06-23 | 1997-01-29 | Syntex Pharma Ltd | Treating tissues with a ranolazine derivative |
US5209933A (en) | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
JPH09188617A (ja) * | 1996-01-08 | 1997-07-22 | Pola Chem Ind Inc | 徐放性医薬組成物 |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
JP2000336032A (ja) * | 1999-05-26 | 2000-12-05 | Kissei Pharmaceut Co Ltd | ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物 |
-
2000
- 2000-03-08 US US09/520,932 patent/US6479496B1/en not_active Expired - Lifetime
-
2001
- 2001-03-07 BR BR0109091-7A patent/BR0109091A/pt not_active Application Discontinuation
- 2001-03-07 AU AU4009201A patent/AU4009201A/xx active Pending
- 2001-03-07 RU RU2002126615/14A patent/RU2002126615A/ru unknown
- 2001-03-07 CA CA002402222A patent/CA2402222C/en not_active Expired - Lifetime
- 2001-03-07 CN CNB018061850A patent/CN1323664C/zh not_active Expired - Lifetime
- 2001-03-07 HU HU0204409A patent/HUP0204409A3/hu unknown
- 2001-03-07 NZ NZ521292A patent/NZ521292A/en not_active IP Right Cessation
- 2001-03-07 WO PCT/US2001/007287 patent/WO2001066093A2/en active IP Right Grant
- 2001-03-07 CZ CZ20022996A patent/CZ20022996A3/cs unknown
- 2001-03-07 MX MXPA02008654A patent/MXPA02008654A/es active IP Right Grant
- 2001-03-07 AU AU2001240092A patent/AU2001240092B8/en not_active Revoked
- 2001-03-07 JP JP2001564746A patent/JP4108980B2/ja not_active Expired - Lifetime
- 2001-03-07 IL IL15157501A patent/IL151575A0/xx unknown
- 2001-03-07 EP EP01914738A patent/EP1263439A2/en not_active Withdrawn
- 2001-03-07 PL PL01357273A patent/PL357273A1/xx not_active Application Discontinuation
-
2002
- 2002-09-06 NO NO20024270A patent/NO20024270L/no not_active Application Discontinuation
-
2004
- 2004-02-10 HK HK04100863A patent/HK1058003A1/xx not_active IP Right Cessation
-
2007
- 2007-09-20 JP JP2007243731A patent/JP2008069159A/ja active Pending
-
2008
- 2008-09-03 AU AU2008212005A patent/AU2008212005A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1443069A (zh) | 2003-09-17 |
CA2402222C (en) | 2009-11-03 |
IL151575A0 (en) | 2003-04-10 |
EP1263439A2 (en) | 2002-12-11 |
NO20024270L (no) | 2002-11-06 |
AU2001240092B2 (en) | 2004-10-14 |
BR0109091A (pt) | 2005-02-15 |
PL357273A1 (en) | 2004-07-26 |
NO20024270D0 (no) | 2002-09-06 |
AU2001240092B8 (en) | 2004-12-02 |
HUP0204409A2 (en) | 2003-05-28 |
HUP0204409A3 (en) | 2005-04-28 |
CA2402222A1 (en) | 2001-09-13 |
JP2008069159A (ja) | 2008-03-27 |
JP2003525896A (ja) | 2003-09-02 |
CN1323664C (zh) | 2007-07-04 |
AU4009201A (en) | 2001-09-17 |
WO2001066093A3 (en) | 2002-03-14 |
US6479496B1 (en) | 2002-11-12 |
AU2008212005A1 (en) | 2008-09-25 |
CZ20022996A3 (cs) | 2003-09-17 |
RU2002126615A (ru) | 2004-03-20 |
NZ521292A (en) | 2008-07-31 |
WO2001066093A2 (en) | 2001-09-13 |
JP4108980B2 (ja) | 2008-06-25 |
MXPA02008654A (es) | 2004-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1058003A1 (en) | Sustained release ranolazine formulations | |
IL180864A0 (en) | Sustained release ranolazine formulations | |
EG24074A (en) | Formulation | |
AU9701101A (en) | Methylphenidate modified release formulations | |
EP1356809A4 (en) | SUSTAINED RELEASE PREPARATIONS | |
IL142268A0 (en) | Ophthalmic formulations | |
HUP0402067A3 (en) | Vaccines | |
GB0000891D0 (en) | Formulation | |
GB0015490D0 (en) | Novel formulations | |
GB0004533D0 (en) | Vaccines | |
GB0022027D0 (en) | Disfectant formulations | |
GB0000031D0 (en) | GLP-2 formulations | |
GB0011333D0 (en) | Controlled release formulations | |
GB0007070D0 (en) | Deodorant formulations | |
GB0008029D0 (en) | New vaccine formulations | |
GB0009431D0 (en) | Sunscreen formulations | |
NZ513664A (en) | Long acting formulations | |
GB0014280D0 (en) | Vaccines | |
GB0006281D0 (en) | Vaccines | |
GB0004124D0 (en) | Formulation | |
GB0007112D0 (en) | Formulation | |
GB0023069D0 (en) | Formulation | |
GB0010846D0 (en) | Formulation | |
GB0001144D0 (en) | Glysophosate formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20210306 |